Could Omega Diagnostics shares make you a fortune?

Omega Diagnostics shares have been on a tear this year. But has the rally run out of steam, or is there still time to buy this market-beating stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Omega Diagnostics (LSE: ODX) shares have been on a tear this year. Investors who were savvy enough to buy the stock in January have seen a total return of over 260% on their money. That’s vastly superior to the market-average return year-to-date.

Omega Diagnostics shares jump on good news 

Omega Diagnostics shares have soared as the company has become a crucial part of the government’s coronavirus strategy. At the beginning of March, the firm became part of the UK Rapid Test Consortium (RTC).

Part of the government’s five-pillar national testing strategy, the RTC, which also counts Oxford University as a member, is working to develop and manufacture a Covid-19 point-of-care antibody test.

But this isn’t the only string to Omega’s bow. The company has also developed rapid testing for HIV and other viruses. At the end of April, the firm confirmed it had inked a material transfer agreement with diagnostic test producer Mologic. The two parties will now work on the development of Mologic’s Enzyme-Linked Immuno-Sorbent Assay diagnostics test.

These deals should help underpin Omega Diagnostics shares. Still, at this point, it’s difficult to place a value on the stock. While the company earned a small profit between 2014 and 2017, the firm reported a loss in 2018 and 2019.

However, analysts believe the company’s new agreements could help it earn revenues of up to £30m. This forecast is based on an assessment of the business’s testing production capacity.

Sales growth 

As Omega reported just £9m of revenues for 2019, a jump to £30m could yield a significant increase in profits for the firm. Historically, Omega has reported an operating profit of around 5%.

On revenues of £30m, this suggests the business could earn somewhere in the region of £1.5m of operating income on this optimistic broker projection. By comparison, Omega Diagnostics shares are currently valuing the business at £84m.

As such, Omega Diagnostics shares look a bit expensive at current levels. Nevertheless, this is only a rough projection, and there’s no reason why the company can’t beat City expectations for the year.

Long term potential 

As of yet, we don’t know how much of an impact on the RTC partnership will have on Omega’s profits. It could end up being a game-changing agreement, especially if it opens doors to produce additional tests for other markets. Considering the company’s experience in the testing market, and existing manufacturing capacity, this is a very real prospect. 

In this most optimistic scenario, the stock may increase further from current levels, depending on the scope of the new contracts, and revenue potential.

Therefore, considering all of the above, Omega Diagnostics shares may have the potential to make you a fortune in the years ahead. However, this is a high-risk, high-reward investment.

It may only be suitable for the most tolerant investors and should be owned as part of a well-diversified portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »